Study S001781

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05912621
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 66
Start: 2023-11-09
Primary completion: 2028-06
Lead sponsor: Stanford University
Conditions: Obesity; Overweight and Obesity; Overweight
Interventions: DRUG:Tirzepatide
Results posted: FALSE

Registered primary outcomes

Change in Adipocyte Size [Baseline and Week 22]
Change in Adipocyte Fat Storage Capacity [Baseline and Week 22]
Assess changes in Regional Fat [Baseline, week 6, and week 22]
Change from baseline on the 2-stage Steady State Plasma Glucose test [Baseline, week 6, and week 22]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.